LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial

R. Dent, Zhi-Ming Shao, P. Schmid, J. Cortés, David W. Cescon, Shigehira Saji, Kyung Hae Jung, T. Bachelot, S. Wang, Ğüvenç Başaran, Y.S. Chae, R.M. Mathiba, S-C. Chen, A. Stradella, N. Battelli, Naoki Niikura, Kangning Zhao, P. Vuković, M. Maxwell, T. Traina